Better detection accounts for increase in cases of thyroid cancer

NewsGuard 100/100 Score

Although still rare, the incidence of thyroid cancer is increasing. In this longitudinal study over 12 years from a large cancer registry, Kent and colleagues used the Ontario Cancer Registry to identify 7422 cases of differentiated thyroid cancer from 1990 to 2001.

Their results show the jump in the incidence rate of this type of thyroid cancer was 146% over the 12-year period, or an annual increase of 13% per year.

In their study, the authors found that small (less than 2 cm), subclinical tumours accounted for the increased incidence, suggesting that advances in medical imaging, rather than a change in disease pattern, may be responsible for the increase.

In a related commentary, How and Tabah discuss how these findings fit within the global body of evidence on thyroid carcinoma incidence. They also list potential explanations for the increasing incidence of papillary thyroid carcinoma. Most importantly, state How and Tabah, discovery and development of specific and sensitive markers — especially molecular and genetic — is urgently needed to further understanding of the basic biology of each subgroup and variant of papillary thyroid carcinoma.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer